On May 18, BioMérieux finalized its acquisition of Specific Diagnostics for approximately $416.8 million, equivalent to 3.2 percent of the French diagnostic firm’s market capitalization as of closing date, paying with a combination of cash and shares issued to Specific Diagnostics shareholders.
Acquiring Specific Diagnostics, a privately held US company and producer of the Specific Reveal Rapid AST system, a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST results directly from positive blood cultures, enhances BioMérieux’s global position in clinical microbiology. The Specific system seamlessly integrates with BioMérieux’s own Sepsis Solution, enabling it to generate same-day AST results from Gram-negative bacteria, according to BioMérieux. “By combining the advanced technology of the Specific Reveal Rapid AST solution for bloodstream infections with our existing solutions, we are increasing the ability of laboratories to deliver results in record time, especially in cases of very critical infections such as sepsis, which require urgent and appropriate treatment,” noted BioMérieux executive vice president and chief medical officer Mark Miller in a statement.
Find out more about this and other recent mergers and acquisitions in the June 2022 Lab Industry Report.